Yi-Ming Chen

Mar 21, 2025 | onlinelibrary.wiley.com | Yi-Ming Chen |Xue Li |Zhi-Gang Xu

References 1, , , , , , , , , Int. J. Mol. Sci. 2023, 24, 6581. 2, , , , , Molecules 2020, 25, 505. 3, , , , , Chem. Soc. Rev. 2022, 51, 2313–2382. 4, , , RSC Adv. 2020, 10, 42644–42681. 5, , , , Mol. Diversity 2024, 28, 229–248. 6, , , , Angew. Chem. 1959, 71, 386. 7, , Chem. Rev. 2019, 119, 9836–9860. 8, , , ACS Omega 2020, 5, 972–979. 9, , , Chem. Rec. 2023, 23, e202300095. 10, , , , , , , J. Org. Chem. 2023, 88, 12709–12715. 11, , , , Org. Biomol. Chem. 2022, 20, 3823–3834.

Jan 9, 2024 | nature.com | Yi-Ming Chen

AbstractNotwithstanding recent advances in direct antiviral specialists (DAAs) for hepatitis C infection (HCV), it is yet a pervasive overall issue in patients with rheumatoid arthritis (RA). Exosomal microRNAs (miRNAs) is associated with HCV infection. However, it remains unknown how miRNAs respond following biologic disease-modifying antirheumatic drug (bDMARD) and targeted synthetic DMARD (tsDMARD) treatment in HCV patients with RA.

Dec 11, 2023 | mdpi.com | Szu-Ling Chang |Chih-Hung Lai |Yi-Ming Chen |Guan-Cheng Lin

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.